


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 8. (Canceled)

9. (Previously Presented): A method for treating retinopathy, comprising administering to a subject in need thereof an effective amount of an agent comprising a tricyclo compound of formula (I)



wherein adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ each independently

- a) consist of two adjacent hydrogen atoms, wherein R² is optionally alkyl, or
- b) form another bond optionally between carbon atoms binding with the members of said pairs;

R⁷ is hydrogen atom, hydroxy, protected hydroxy, or alkyloxy, or optionally form oxo with R¹;

R⁸ and R⁹ are each independently a hydrogen atom or hydroxy;

R^{10} is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $-\text{CH}_2\text{O}-$;

Y is oxo, (hydrogen atom, hydroxyl), (hydrogen atom, hydrogen atom), or a group of the formula $\text{N}-\text{NR}^{11}\text{R}^{12}$ or $\text{N}-\text{OR}^{13}$;

R^{11} and R^{12} are each independently a hydrogen atom, alkyl, aryl or tosyl;


R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} are each independently a hydrogen atom or alkyl;

R^{24} is a ring that is optionally substituted and optionally contain one or more hetero atom(s); and

n is 1 or 2,

wherein Y, R^{10} and R^{23} are optionally, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula $-\text{CH}_2\text{Se}(\text{C}_6\text{H}_5)$, and alkyl substituted by one or more hydroxyl, or a pharmaceutically acceptable salt thereof.

10. (Canceled)



12. (Previously Presented) The method of claim 9, wherein the retinopathy is ischemic retinopathy.

13. (Previously Presented) The method of claim 12, wherein the ischemic retinopathy is selected from the group consisting of diabetic retinopathy, fundus hypertonicus, central retinal artery occlusion, central retinal vein thrombosis, retinal peripheral vascular occlusion and retinopathy of prematurity.

14. (Previously Presented) The method of claim 9, wherein said administering is by local administration to the eye.

15. (Currently Amended) The method of claim 14, wherein said effective amount is comprises 0.001 to 10 ~~w/v%~~ % weight per volume of the tricyclo compound of formula (I) administered 1 to 6 times per day.

16. (Currently Amended) The method of claim 14, wherein said effective amount is comprises 0.005 to 5 ~~w/v~~ % weight per volume of the tricyclo compound of formula (I) administered 1 to 6 times per day.

17. (Previously Presented) The method of claim 9, wherein said effective amount is a dose ranging from 0.0001 to 1000 mg.


18. (Previously Presented) The method of claim 17, wherein said dose is administered 2 to 4 times per day.

19. (Previously Presented) The method of claim 9, wherein said effective amount is a dose ranging from 0.001 to 500 mg.

20. (Previously Presented) The method of claim 19, wherein said dose is administered 2 to 4 times per day.

21. (Previously Presented) The method of claim 9, wherein said agent further comprises one or more additives selected from the group consisting of an isotonicizing agent, a buffer, a preservative, a tackifier, a hyaluronic acid or salt thereof, and a mucopolysaccharide.

22. (Currently Amended) The An agent of claim 3 suitable for treating retinopathy comprising a tricyclo compound of formula (I)



wherein adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ each independently

a) consist of two adjacent hydrogen atoms, wherein R² is optionally alkyl, or

b) form another bond optionally between carbon atoms binding with the members of said pairs;

R⁷ is hydrogen atom, hydroxy, protected hydroxy, or alkyloxy, or optionally form oxo with R¹;

R⁸ and R⁹ are each independently a hydrogen atom or hydroxy;

R¹⁰ is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula -CH₂O-;

Y is oxo, (hydrogen atom, hydroxyl), (hydrogen atom, hydrogen atom), or a group of the formula N-NR¹¹R¹² or N-OR¹³;

R¹¹ and R¹² are each independently a hydrogen atom, alkyl, aryl or tosyl;

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ are each independently a hydrogen atom or alkyl;

R²⁴ is a ring that is optionally substituted and optionally contain one or more hetero atom(s); and

n is 1 or 2,

wherein Y, R¹⁰ and R²³ are optionally, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula -CH₂Se(C₆H₅), and alkyl substituted by one or more hydroxy,

or a pharmaceutically acceptable salt thereof,

wherein said agent further comprises one or more additives selected from the group consisting of an isotonicizing agent, a buffer, a preservative, a tackifier, a hyaluronic acid or salt thereof, and a mucopolysaccharide.

SUPPORT FOR THE AMENDMENTS

Claims 1, 2, 5 and 10 were canceled previously.

Claim 3, 4, and 6-8 are canceled herein.

Claims 15, 16, and 22 have been amended.

The amendment of Claims 15 and 16 is supported by the corresponding claims as previously filed and by page 12, line 8 to page 13, line 2. The amendment of Claim 22 is supported by the corresponding claim and Claim 3 as previously filed and by page 12, line 8 to page 13, line 2.

No new matter has been entered by the present amendment.